2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 125

Correlation Of Findings In Clinical and High Resolution Ultrasonography Examinations Of The Painful Shoulder
Abstract Number: 2285

Correlation Of Individual Health Assessment Questionnaire (HAQ) Questions With Outcome Measures In Rheumatoid Arthritis: Implications For Instrument Reduction
Abstract Number: 1957

Correlation Of Structural Abnormalities Of The Wrist and Metacarpophalangeal Joints Evaluated By High-Resolution Peripheral Quantitative Computed Tomography, 3 Tesla MRI and Conventional Radiographs In Rheumatoid Arthritis
Abstract Number: 1741

Correlation Of The Interferon Gene Signature With Systemic Lupus Erythematosus Disease Activity Is Dependent On The Associated Level Of The BAFF Gene Transcript
Abstract Number: 2240

Correlative Analysis Of Swollen Joints Between Clinical Examination and Musculoskeletal Ultrasound For Rheumatoid Arthritis
Abstract Number: 350

Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis
Abstract Number: 1585

Corticosteroid Use Across 52 Weeks Of Belimumab Therapy In Patients With Systemic Lupus Erythematosus: Combined Analyses From The BLISS Trials
Abstract Number: 1461

Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population
Abstract Number: 999

Cost Consideration For Biologics For Patients With Rheumatoid Arthritis In a Pharmacy Benefit Management Setting
Abstract Number: 108

Cost-Effectiveness Analysis Of Diagnostic Tests In The Work-Up Of Patients With Intermediate Risk Of Developing Rheumatoid Arthritis
Abstract Number: 2646

Cost-Effectiveness Analysis Of Triple Therapy Versus Etanercept Plus Methotrexate In Early Aggressive Rheumatoid Arthritis: Analysis Based On The TEAR Trial
Abstract Number: 1004

Cost-Effectiveness Analysis Of Two Rituximab Based Therapeutic Regimens For Longstanding Rheumatoid Arthritis
Abstract Number: 827

Cost-Effectiveness and Cost-Utility Of a One-Year Coaching Program For Healthy Physical Activity In Rheumatoid Arthritis
Abstract Number: 1771

Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany
Abstract Number: 856

Cost-Effectiveness Of Urate Lowering Strategies For The Management Of Gout

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].